A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus

References

• McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605–16
   PubMed Web of Science ®Google Scholar
• Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062–71
   PubMed Web of Science ®Google Scholar
• Glass S, Rosenblum G. The rational use of oral estrogens in the menopause. West J Surg Obstet Gynecol 1943;51:4–7
   Google Scholar
• Sturdee DW, Wade-Evans T, Paterson ME, et al. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. Br Med J 1978;1:1575–7
   PubMed Web of Science ®Google Scholar
• Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones:results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982–8
   PubMed Web of Science ®Google Scholar
• Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686–92
   Google Scholar
• Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994;84:987–95
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy:Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 49–57
   Google Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy:Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 58–66
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women:the Women’s Health Initiative:a randomized trial. JAMA 2003;289:2673–84
   Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:the Women’s Health Initiative Randomized Trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Design of the Women’s Health Initiative Clinical Trial and Observational Study. The Women’s Health Initiative Study Group. Control Clin Trials 1998;19:61–109
   PubMedGoogle Scholar
• Lobo RA, Bush T, Carr BR, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13–24
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate:two-year substudy results. Fertil Steril 2003;80:1234–40
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
   PubMed Web of Science ®Google Scholar
• Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–79
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668–76
   PubMed Web of Science ®Google Scholar
• British Medical Association. British National Formulary (BNF). London, 2004
   Google Scholar
• Scottish Medicines Consortium. Summary of Advice. Conjugated oestrogen, medroxyprogesterone (Premique Low Dose) 8 Nov 2004. Available from www.scottishmedicines.org.uk/%20updocs/Premique%20low%20dose.pdf [Last accessed 09 June 2005]
   Google Scholar
• Lawrence M, Jones L, Lancaster T, et al. Hormone replacement therapy:patterns of use studied through British general practice computerized records. Fam Pract 1999;16:335–42
   PubMed Web of Science ®Google Scholar
• Loh FH, Chen LH, Yu SL, et al. The efficacy of two dosages of a continuous combined hormone replacement regimen. Minnesota:Health Technology Advisory Committee, 2002
   Google Scholar
• Wren B, Brown L. Compliance with hormonal replacement therapy. Minnesota:Health Technology Advisory Committee, 1991
   Google Scholar
• Vihtamaki T. Why do postmenopausal women discontinue HRT? Minnesota:Health Technology Advisory Committee, 1999
   Google Scholar
• Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999;6:282–9
   Google Scholar
• Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for post-menopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325–8
   PubMedGoogle Scholar
• Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102–6
   PubMed Web of Science ®Google Scholar
• Sturdee DW. The importance of patient education in improving compliance. Climacteric 2000;3(Suppl 2):9–13
   PubMedGoogle Scholar
• Health Technology Advisory Committee. Postmenopausal hormone replacement. Minnesota:Health Technology Advisory Committee, 2002
   Google Scholar
• den Tonkelaar I, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol 2000;95:507–12
   PubMed Web of Science ®Google Scholar
• Li C, Samsioe G, Lidfelt J, et al. Important factors for use of hormone replacement therapy:a population-based study of Swedish women. The Women’s Health in Lund Area (WHILA) Study. Menopause 2000;7:273–81
   Google Scholar
• Regan MM. Why do older women discontinue HRT? J Women’s Health Gend Based Med 2001;10:343–50
   PubMedGoogle Scholar
• Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77–86
   PubMed Web of Science ®Google Scholar
• Doren M, Schneider HP. The impact of different HRT regimens on compliance. Int J Fertil Menopausal Stud 1996;41:29–39
   PubMed Web of Science ®Google Scholar
• Abacus International. Data on file. 2005
   Google Scholar
• MIMS, Monthly Index of Medical Specialities. London:Haymarket Medical Publications Ltd, 2004
   Google Scholar
• Netten A, Curtis L. Unit costs of health and social care 2003. Canterbury, UK:PSSRU Personal Social Services Research Unit, 2003
   Google Scholar
• ISD. Costs book 2003. Available from:www.isdscotland.org/isd/files/Costs_2003.pdf [Last accessed 09 June 2005]
   Google Scholar
• Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836–40
   PubMed Web of Science ®Google Scholar
• Consensus Conference on Hormone Replacement Therapy. Final Consensus Statement. Available from www.rcpe.ac.uk. 2003 [Last accessed 22 Sept 2005]
   Google Scholar
• UK Department of Health. Population figures at SHA and PCO level for England and Wales. Available from:www.dh.gov.uk/PublicationsAndStatistics/Statistics/ StatisticalWorkAreas/StatisticalHealthCare/StatisticalHealthCareArticle/fs/en?CONTENT_ID=4001584&chk=LubbNc [Last accessed 09 June 2005]
   Google Scholar
• Adelphi Research UK. Data on file. 2005
   Google Scholar